v3.26.1
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2026
Stockholders' Equity Note [Abstract]  
Schedule of Stock-Based Compensation Expense

The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations (in thousands):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Cost of revenue

 

$

383

 

 

$

360

 

 

$

763

 

 

$

660

 

Research, development and clinical trials
 expenses

 

 

1,065

 

 

 

1,189

 

 

 

2,535

 

 

 

2,505

 

Selling, general and administrative expenses

 

 

7,158

 

 

 

7,823

 

 

 

15,260

 

 

 

15,165

 

 

 

$

8,606

 

 

$

9,372

 

 

$

18,558

 

 

$

18,330